Marie-Laure Pochon elected as Lundbeck's new EVP of Commercial Operations
Lundbeck's Executive Management Group reduced from six to four members
H. Lundbeck A/S (Lundbeck) announces the appointment of Marie-Laure Pochon as new Executive Vice President, Commercial Operations, as of today. Marie-Laure Pochon is an ESPCI graduate[i], holds an MBA from HEC Paris and is Chief Executive of Lundbeck France and Regional Vice President for France, Belgium, UK, Spain, Italy, Turkey & Germany at Lundbeck. Marie-Laure has delivered great results since joining Lundbeck in 2007. She has realized high growth and improved the profitability of our very important French affiliate. She has furthermore successfully led the Western Europe and Turkey region. Lundbeck will in the coming months execute on many new opportunities to ensure successful implementation of Lundbeck's strategy and secure long-term growth. To further strengthen the execution of Lundbeck's strategy, it has been decided to reduce Lundbeck's Executive Management from six to four members. R&D activities will be concentrated under the leadership of Anders Gersel Pedersen, EVP, Research & Development, in line with the integrated approach of Lundbeck's R&D Strategy. Peter Høngaard Andersen will leave Executive Management, but continue as part of Lundbeck's corporate management team as SVP, External Scientific Relations & Patents, where he will provide focused leadership of the expansion of external public and private research partnerships and collaborations. Lars Bang will leave Executive Management, but continue to play an important role in Lundbeck's corporate management team as SVP, Supply Operations & Engineering, leading Lundbeck's global supply chain. "I am very pleased that Marie-Laure Pochon is joining Lundbeck's Executive Management Group, where she can contribute with her strong commercial experience from a long career in the pharmaceutical industry," says Ulf Wiinberg, President & Chief Executive Officer at Lundbeck. Lundbeck's Executive Management Group now consists of * Ulf Wiinberg, President & CEO * Anders Götzsche, Executive Vice President, CFO * Anders Gersel Pedersen, Executive Vice President, R&D * Marie-Laure Pochon, Executive Vice President, Commercial Operations Lundbeck contacts Investors: Media: Palle Holm Olesen Mads Kronborg Chief Specialist, Investor Relations Media Relations Manager palo@lundbeck.com mavk@lundbeck.com +45 36 43 24 26 +45 36 43 28 51 Magnus Thorstholm Jensen Simon Mehl Augustesen Investor Relations Officer International Media Specialist matj@lundbeck.com smeh@lundbeck.com +45 36 43 38 16 +45 36 43 49 80 Jacob Tolstrup Vice President jtl@lundbeck.com +1 847 282 5713 About Lundbeck H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases. Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with CNS disorders. In 2010, the company's revenue was DKK 14.8 billion (approximately EUR 2.0 billion or USD 2.6 billion). For more information, please visit www.lundbeck.com. -------------------------------------------------------------------------------- [i] ESPCI : The école supérieure de physique et de chimie industrielles de la ville de Paris or ESPCI ParisTech (The City of Paris Industrial Physics and Chemistry Higher Educational Institution) [HUG#1544655]